Pieris Pharmaceuticals (PIRS) Rating Increased to Strong-Buy at BidaskClub

Retrieved on: 2018-02-14 21:07:30

Tags for this article:

Immunology

TIAA

Anticalin

Pieris Pharmaceuticals

Click the tags to see associated articles and topics

Pieris Pharmaceuticals (PIRS) Rating Increased to Strong-Buy at BidaskClub. View article details on hiswai:

Excerpt

<div><b>Millennium Management</b> LLC now owns 699,771 shares of the biotechnology company's stock worth $5,283,000 after purchasing an additional 256,622 shares in the last quarter. TIAA CREF Investment Management LLC grew its stake in Pieris Pharmaceuticals by 25.1% during the 4th quarter.</div>

Article found on:

View Original Article